Twitter Logo Youtube Circle Icon LinkedIn Icon

The Legal 500 Hall of Fame Icon The Legal 500 Hall of Fame highlights individuals who have received constant praise by their clients for continued excellence. The Hall of Fame highlights, to clients, the law firm partners who are at the pinnacle of the profession. In the United Kingdon, the criteria for entry is to have been recognised by The Legal 500 as one of the elite leading lawyers for eight years. These partners are highlighted below and throughout the editorial.
Click here for more details

United Kingdom > London > TMT (technology, media and telecoms) > Pharmaceuticals and biotechnology > Law firm and leading lawyer rankings

Editorial

Other

Index of tables

  1. Pharmaceuticals and biotechnology
  2. Leading individuals: Hall of Fame
  3. Leading individuals
  4. Next Generation Partners
  5. Rising stars

Rising stars

  1. 1

At Allen & Overy LLP, Jim Ford leads the London IP practice and is co-chair of the global life sciences group and Marc Doring heads the UK IP litigation team. The group offers the full spectrum of specialisms; mergers and acquisitions, commercial transactions, IP, financing and regulatory matters. Matthew Appleton focuses on corporate transactions for life sciences clients and the 'excellent' Marjan Noor is highly rated for her handling of IP and regulatory matters. Neville Cordell and senior associate Rafi Allos tackle IP litigation together with regulatory work. Many of the team have science backgrounds -  there is a team of science analysts based in Belfast and the team has a specific focus on the area of gene editing. It also offers a comprehensive range of expertise from regulatory to distribution and advertising in respect of the challenges associated with the medicinal applications of cannabis.

Practice head(s):Jim Ford

Other key lawyers:Marc Doring; Marjan Noor; Matthew Appleton; Neville Cordell; Rafi Allos

Testimonials

'Top quality work product. Sensible. Thoughtful. Good at anticipating clients needs.'

'Michael Snook is mature, easy to deal with and very straightforward.'

Key Clients

Circassia

Grünenthal Pharma

Regeneron Pharmaceuticals

Pfizer

Exscientia

Almac

BTG

Sanofi

Zimmer Biomet

Premaitha Health plc (now Yourgene Health)

Work highlights

  • Represented Premaitha Health, which has developed the first CE marked non-invasive prenatal test for chromosomal aneuploidies. It defended patent infringement claims under five separate patents brought by a number of parties, but the matter was settled prior to a Court of Appeal hearing.  
  • Successfully acted for Regeneron, the US biopharmaceutical company, in bringing patent infringement proceedings against Kymab Limited, a UK biotechnology company.
  • Acting for a global pharma company in a Supreme Court appeal in respect of a blockbuster drug.
  • Advising BTG plc on the recommended offer by Boston Scientific Corporation. The boards reached agreement on the terms of a recommended offer to be implemented under the City Code on Takeovers and Mergers by way of a UK scheme of arrangement. Advice to the client included competition issues in a deal valued at £3.3bn.
  • Advised GN Hearing on all aspects (from term sheet to signed documents) of its multi-agreement “Smart Hearing” collaboration with Cochlear.  This included complex IP licensing arrangements to take account of perpetual cross-licensing.

Bird & Bird LLP is known for its 'hard core' IP strength in the life sciences sector. Mark Hilton, who co-heads the life sciences and healthcare group with Sally Shorthose, is highly regarded for his deft handling of complex patent litigation. Noted for her 'good negotiating skills' Shorthose has a focus on the transactional side of IP and regulatory regimes. Corporate partner James Baillieu has joined the team from Norton Rose Fulbright. Other members of the patent disputes group include Tim Harris , Eleanor Root  and associate Chris de Mauny. In addition to its IP skills, the team also handles a range of commercial work such as collaborations and licensing matters together with regulatory matters.

Practice head(s):Mark Hilton; Sally Shorthose

Other key lawyers:Tim Harris; Eleanor Root; Chris de Mauny; James Baillieu

Testimonials

'A strong team with a wealth of technical understanding of industry areas and a stellar track record of work in key areas.'

'B&B are consistently high quality. You know what you are going to get - whilst the fees are high, they will leave no stone unturned progressing shrewd and practical strategies.'

'They remain at the pinnacle of the profession as regards their life sciences work.'

'Mark Hilton provides calm, clear-headed advice and has a keen eye for detail and an understanding of the broader context.'

'Mark Hilton is a match for anyone as a pharma-focused patent litigator. His deep industry knowledge sets him apart from much of the rest of the field. He is calm under pressure and is able to avoid being sidetracked, which is quite a skill in complex patent litigation. There is no one better at 4D chess.'

Key Clients

Allergan

Actavis (acquired by Accord Healthcare)

Merck KGaA

eZono AG

Guy's and St Thomas's NHS Foundation Trust

Fisher & Paykel Healthcare

Calero Software

Mercury Innovations

Teva

Work highlights

  • Acting for Allergan in High Court revocation proceedings brought by Aspire and Accord in respect of a patent owned by Allergan for an enhanced ophthalmic solution which has approximate annual UK sales of £16.5m. This litigation is complicated by regulatory issues and approvals.
  • Assisting eZono on a number of alliance and collaboration agreements with international partners for the licensing and integration of its guiding procedural ultrasound technology into partner products. The work included drafting and negotiating collaboration and alliance agreements and  addressing complex IP licensing and ownership arrangements. The Hong Kong office assisted as a number of the partners are based in Asia-Pacific.
  • Advising Guy's and St Thomas's NHS Foundation Trust on a range of matters including commercial projects for the provision of healthcare to technology agreements and procurement.

  • Advised Calero Software, a leading global provider of Communications and Cloud Lifecycle Management software and managed services, in acquiring the entire issued share capital of Scotland-based Veropath Limited, a leading provider of telecom expense management solutions throughout the UK and Europe.

With 'enormous strength in the pharma and biotech space'  Bristows LLP attracts acclaim from clients as a go-to practice. Laura Anderson and 'outstanding' Liz Cohen are the joint heads of the life sciences group and Brian Cordery who 'knows his stuff' jointly heads patent litigation with Myles Jelf. The team offers an all-round service to clients covering the core areas of transactional, regulatory and IP expertise. Its skills also extend to areas where tech intersects with life sciences or healthcare and the handling of, for example, medical data. 'Excellent regulatory expert' Alex Denoon heads the regulatory group and with a PhD in molecular biology, litigator Dr Robert Burrows  is 'one of the most knowledgeable solicitors in the pharma/biotech space'. The 'talented' Gemma Barrett is a litigator within life sciences and 'creative thinker' Greg Bacon  and senior associate Rachel Mumby are also recommended.

Practice head(s):Laura Anderson; Liz Cohen

Other key lawyers:Brian Cordery; Alex Denoon; Rob Burrows; Gemma Barrett; Greg Bacon; Rachel Mumby; Olivia Henry

Testimonials

'They have well-qualified solicitors with technical backgrounds who are familiar with the science immediately. They are a large enough team to cope with large cases and demanding clients. There are excellent juniors of whom the more senior team are very supportive. A huge pleasure to work with and they get great results.'

'The Bristows team provided exceptionally good work. All team members were very responsive and open for discussions. Their written work product was likewise spotless and, unlike the work product of most other firms that I have worked with, there was no need for fine tuning.'

'Bristows was able to grasp our technically complex case quickly and helped to advance our global litigation strategy even beyond the UK with their vast experience in this field.'

'There is a real focus on life sciences and technology at the firm, with all the specialist teams a pharmaceutical company needs in the same place - IP, regulatory, competition. They are always willing to provide excellent, current and useful training.'

'The team really cares about doing a good job and always go the extra mile. Although a partner-led service, you also get to know the associates who are doing the work.'

'Rob Burrows is one of the most knowledgeable solicitors in the pharma/biotech space. He explains difficult concepts so well to clients and is easy to work with.'

'Greg Bacon is a creative thinker - he can propose innovative options as solutions.'

'Alex Denoon is an excellent regulatory expert.  It's a great experience working with him.'

'Rachel Mumby is a talented solicitor- technically excellent and great with clients.'

'Olivia Henry is a brilliant young solicitor with great knowledge and ability.  One to watch'.

'Every one of Dominic Adair, Gregory Bacon and Gemma Barrett is particularly talented in their area.'

'Dominic Adair did a great job in coordinating all activities of our case. He is very pleasant to work with. He is a bright mind and yet remained very modest. I can highly recommend him for any IP litigation in the UK and will certainly work with him again in the future.'

'Dom Adair is technically gifted, understands issues quickly and gives great commercial advice.'

'Brian Cordery is incredibly responsive and diligent, knows his stuff and thinks the case through carefully.'

'Gemma Barrett provides very clear and commercial advice.'

 

Key Clients

Novartis

Celltrion

Johnson & Johnson (Janssen Sciences)

AstraZeneca

Teva Pharmaceuticals

Chugai

UCL Business

Fresenius

Genomics England

Syncona

GSK

Emmanuelle Charpentier

Google and DeepMind

IBM Watson

Work highlights

  • Advising Genomics England (UK Department of Health) on a range of matters including on a commercial technology collaboration with IQVIA, under which IQVIA will develop its platform to accommodate genomic data and advised on the IT and IP  issues  relating to its pioneering PanelApp.
  • Assisted Searle (Pfizer) and Janssen (Johnson & Johnson) in their successful defence of SPC revocation proceedings commenced by Sandoz and Hexal. The matter concerned Janssen’s blockbuster medication for the treatment of HIV-1. The Court of Appeal referred a question on the matter to the European Court.
  • Advised Syncona, as lead investor, in the £14m Series A financing for OMass Therapeutics Limited. This financing is intended to enable OMass to develop a pipeline of novel drug development programmes.
  • Represent EVER Neuro, a company focused on the research, development, production and commercialisation of products in the areas of neurology, critical care, anesthesia and oncology.  Ever Neuro holds a Marketing Authorisation medicine granted by the MHRA in respect of a generic version of an existing medicine. Orion holds the Marketing Authorisation in respect of the existing medicine. Orion has asked the Court to revoke the Marketing Authorisation granted to the client who is an interested party in the proceedings. In a complex case,  Orion asked for a question to be referred to the CJEU to seek to change the current CJEU jurisprudence.
  • Continues to act for long-standing client Novartis Pharma AG, with the enforcement of its patents for its blockbuster medicines.

The life sciences and healthcare division of CMS, headed by Sarah Hanson and Robert Stephen, is noted for its 'excellent and commercial advice and efficiency'. It offers specialists in all areas pertinent to life sciences and healthcare including transactional work, IP and regulatory regimes. Shuna Mason specialises in product liability and regulations and Gareth Morgan focuses on IP protection and regulatory compliance. Caroline Hobson provides sector specific competition advice, for which Carina Healey in Glasgow is also noted. The team is involved in advising on projects where healthcare and technology meet.

Practice head(s):Sarah Hanson; Robert Stephen

Other key lawyers:Shuna Mason; Gareth Morgan; Omar Qureshi; Caroline Hobson; Carina Healey

Testimonials

'The pharmaceutical and biotechnology advisors have in-depth knowledge of the risks and challenges faced by the industry and by global companies in the industry. Their European network of advisors provides the ability to advise within multiple jurisdictions without the administrative burden of engaging separate law firms for each piece of advice or project.'

'Sarah Hanson has acted as our relationship partner and has always responded quickly and helped to select appropriate advisors within the CMS network for each instruction.'

'Gareth Morgan has displayed exceptional in-depth knowledge of our products and the science behind them, which makes his IP and regulatory advice invaluable.'

Key Clients

Autolus

Francis Crick Institute

GlaxoSmithKline

Johnson & Johnson

Medtronic

Otsuka

The Wellcome Trust

Work highlights

  • Acted for Silence Therapeutics, a leader in RNA therapeutics for the treatment of serious diseases, in patent infringement and revocation proceedings brought against Alnylam Pharmaceuticals. As well as the UK litigation, co-ordinated claims brought in the Netherlands and Portugal and related European Patent Office proceedings.
  • Advised GlaxoSmithKline Plc on the UK’s only ever 'reverse patent settlement' investigation and one of the most high-profile UK prohibitive competition law inquiries, and on its appeal to the Competition Appeal Tribunal and current reference to the European Court of Justice.
  • Continuing to advise long-standing client University College London on a number of high-profile strategic research collaborations involving various academic institutions with significant funding from the UK research councils and charity partners.
  • Successfully defended Sandoz against both patent infringement proceedings and a regulatory challenge mounted against its pharmaceutical product authorisations. Also advising on the client's claim on the cross-undertakings in damages against Napp Pharmaceuticals.

Alan Montgomery is the global co-head of the Herbert Smith Freehills LLP pharmaceuticals and healthcare sector team, together with Shaun McVicar in Melbourne. It is home to a world-class patent litigation team acting for global pharmaceutical companies;  Sophie Rich and Sebastian Moore are two of the key patent litigators whilst Montgomery handles an impressive range of M&A, restructuring, joint venture and commercial mandates in the life sciences sector. Jonathan Turnbull's expertise includes protection of rights in small molecule and biological products and Chris Parker handles a broad range of disputes in the sector.

Practice head(s):Alan Montgomery

Other key lawyers:Sophie Rich; Sebastian Moore; Jonathan Turnbull; Chris Parker

Testimonials

'A top-tier team, very impressive.'

'Mark Shillito, Joel Smith and Andrew Moir are all brilliant lawyers, strategic thinkers with great client skills.'

Key Clients

Ariosa Diagnostics, Inc. (part of the Roche group)

AbbVie

Gilead Sciences

Sanofi

Genus Plc

Strides Pharma Science

Biogen

F Hoffmann-La Roche

Abbott Laboratories

Work highlights

  • Representing Ariosa (a member of the Roche group) in patent infringement proceedings brought against it in relation to its Harmony non-invasive prenatal test.
  • Advised Aurobindo Pharma on its acquisition of the commercial operations and certain supporting infrastructure of Apotex in the Netherlands, Belgium, Spain, Poland and the Czech Republic, and entry into related commercial and licensing arrangements.
  • Coordinating the enforcement and defence of Gilead's SPCs that protects Gilead's HIV medicines in Europe. Litigation is being conducted in numerous European countries.
  • Advising Strides and related entities in a series of complex cross-border transactions which involve advice on mergers, acquisition finance and product supply arrangements.
  • Advising F Hoffmann La-Roche AG and Roche Products Limited on their defence against Pfizer Limited's claim in the UK High Court for so-called 'Arrow declarations' relating to pending European Patent applications owned by Roche.

Hogan Lovells International LLP is home to a blend of IP litigation, product liability, regulatory and transactional skills backed up by the firm's global network and is consequently highly rated for 'a well-rounded' service. Stephen Bennett has a focus on contentious cases involving patent protection and dealing with SPCs and generics (he headed the team that was successful in the landmark UK Supreme Court decision for Eli Lilly in relation to generic attacks on its oncology product). John Meltzer  and Matthew Felwick are well known for their specialism in relation to product liability in the life sciences sector, and counsel Jane Summerfield deals with regulatory matters relating to clinical trials, marketing authorisations, manufacturing and distribution.

Practice head(s):Stephen Bennett; Matthew Felwick

Other key lawyers:John Meltzer; Jane Summerfield

Testimonials

'The Hogan Lovells London team is extremely experienced in life sciences and clearly understand our needs. They have a very pragmatic approach and the partners are generally easily reachable - their response time in cases of urgent matters is very good.'

'The team's strength is that they are reliable and knowledgeable in their area of expertise. They have a good understanding of our business and provide the advice that we are looking for in a satisfactory way -  not always the case with other firms (surprisingly). Individuals are responsive and trustworthy.'

Key Clients

Eli Lilly

Merck Sharp & Dohme

Novartis

LabCorp

Bristol-Myers Squibb

The Association of BritishPharmaceutical Industry

Amgen

Akevia

Mylan

Zimmer Biom

Work highlights

  • The team has won a landmark UK Supreme Court decision for Eli Lilly in relation to the generic attacks on its oncology product, Alimta.
  • Advising the Association of the British Pharmaceutical Industry and a number of international pharmaceutical companies on the implications of Brexit for the entire UK pharmaceutical industry. This has included advising on the process from both a UK and EU perspective, and helping to identify the key issues that will need to be addressed in the withdrawal agreement.
  • Assisted an international pharmaceutical company negotiate an acceptable price with the Department for Health and Social Care for an innovative cancer drug.
  • Acting for Zimmer Biomet and various European subsidiaries in relation to personal injury claims concerning Biomet's metal-on-metal prosthetic hip replacements. The team is coordinating the defence of claims across Europe.
  • Routinely advises clients in the medical devices sector on their engagement with the accreditation and conformity assessment regulators, in connection with questions raised about transfers of medical devices certificates. Also advises on data protection and privacy matters.

The Simmons & Simmons healthcare and life sciences group is headed by Michael Gavey (together with Alexandre Regniault  in Paris). Its client roster ranges from major pharmaceutical and medical device and biotech companies to healthcare operators and charities such as the Institute of Cancer Research. Gavey also heads the IP team and digital health group and assists clients with IP-related transactions, regulatory regimes and compliance. Michael Burdon and Scott Parker deal with patent litigation, often involving multiple jurisdictions. Charles Mayo is a corporate partner who advises on a wide range of commercial and finance matters. Associate Lydia Torne is noted for her IP transactional and regulatory compliance work involving a range of healthcare products.

Practice head(s):Michael Gavey

Other key lawyers:Charles Mayo; Michael Burdon; Scott Parker

Key Clients

Boston Scientific Corporation

Gilead

Acelity

GlaxoSmithKline

Alzheimers’ Research UK (ARUK)

Genmab A/S

The Institute of Cancer Research

ViiV Healthcare

Peel Hunt

Venture Life Group plc

Work highlights

  • Advising on multi-jurisdictional patent litigation for Boston Scientific’s transcatheter aortic replacement technology against Edwards Lifesciences LLC.  Obtained successful outcomes in the UK High Court and Court of Appeal. There is an ongoing dispute between the parties in the UK regarding the amount of damages Edwards will pay Boston Scientific, and whether Edwards’ new product  infringes Boston Scientific’s patents.
  • Advising Gilead in UK litigation against a number of generics in respect of its SPCs protecting Gilead’s HIV drug, TRUVADA.
  • Advising GlaxoSmithKline on its strategic research collaborations including involving AI and on several multi-stakeholder projects funded under the EU Innovative Medicines Initiative and Horizon 2020 and on the impact of Brexit.
  • Working with Alzheimer’s Research UK to establish the Dementia Research Institute.
  • Continuing to advise long-standing client Genmab A/S in connection with various licences, collaboration agreements and commercialisation arrangements with various partners. The  advice includes assisting with manufacturing and supply arrangements, technology transfer arrangements and commercialisation agreements in respect of approved antibodies and pipeline products and technologies.

The Arnold & Porter team is led by Ian Dodds-Smith who is considered a 'luminary' when it comes to regulatory and product liability cases. His expertise covers UK and European regulatory regimes and his product liability experience includes numerous group actions conducted in the UK and Europe. Lincoln Tsang is also know for his regulatory and enforcement work. He is a former senior regulator and advises clients on a raft of sectors;  pharmaceuticals, biotechnology, medical devices, in vitro diagnostic devices, cosmetics and food including on public policy issues. Other team members include Adela Williams who is a registered medical practitioner specialising in regulatory regimes and group actions and Jacqueline Mulryne  who has a focus on the effects of decisions by regulatory bodies.

Practice head(s):Ian Dodds-Smith

Other key lawyers:Lincoln Tsang; Adela Williams; Jacqueline Mulryne

Key Clients

Amicus

Orion

Bayer plc

GMP-Orphan

Boston Scientific

Grünenthal GmbH

Pfizer/Pharmacia

Novartis

Insmed

Work highlights

  • Acting for Amicus in an EU General Court case relating to a request for access to documents under the EMA’s disclosure policy. This is one of a group of cases against the EMA relating to disclosure of documents, that will lead to key decisions in this area. The case relates to disclosure of the client’s clinical study reports for its lead product, Galafold for the treatment of Fabry’s disease.
  • Continuing to defend the regulatory data protection period that Orion believes attaches to one of its important products, Dexdor, that is used to sedate in intensive care. The case has become even larger; there is now a substantial UK element and the case has been extended to many EU member states.
  • Advising Bayer on a challenge in the English courts against various clinical commissioning groups, concerning reimbursement policies. The case concerned the groups’ decision to recommend bevacizumab, a product that is not licensed for ophthalmologic indications, over and above the client’s licensed product for these indications.
  • Advised GMP-Orphan on its application to the European General Court for the annulment of a decision of the European Commission to grant a marketing authorisation for the client’s drug Cuprior - which treats Wilson’s Disease -  without orphan designation.
  • Advising a global pharmaceutical client on matters relating to the supply Factor VIII and IX blood products in 1970s to 1990s,  now the subject of a public Inquiry.

The Baker McKenzie team provides a blend of corporate, commercial and regulatory expertise to its healthcare clients backed by its extensive global network. Hiroshi Sheraton, who heads the sector group, provides deep experience of IP and regulatory regimes to global life sciences and pharma companies, and Jane Hobson focuses on cross-border mergers and acquisitions and other commercial transactions such as licensing and joint ventures. Duncan Reid-Thomas handles tech and IT-related commercial work including healthtech.

Practice head(s):Hiroshi Sheraton

Other key lawyers:Jane Hobson; Duncan Reid-Thomas

Key Clients

GSK

IQVIA

Zimmer Biomet

CSL

Cochlear

Novo Nordisk

Shionogi

Deepmind (part of Alphabet Group)

AstraZeneca UK Ltd

Takeda

Work highlights

  • Advised Astellas, a listed Japanese pharmaceutical company, as lead counsel on the acquisition of the venture-capital backed Quethera Limited. Quethera is a gene therapy company headquartered in the UK.
  • Advising IQVIA on multiple aspects of database services being built in the field of oncology. The work includes the drafting of agreements with healthcare organisations and technology suppliers and regulatory and data privacy compliance advice.
  • Advised CSL and its flu vaccines division, Seqirus, on a number of significant IP-related matters; advising on an exclusive licence agreement for production of recombinant C1 esterase and advising Seqirus on the technology transfer of its flu cell culture manufacturing technology to a Japanese partner.
  • Advised Cochlear on IP, commercial, corporate, competition and regulatory matters in relation to a new agreement to significantly expand their Smart Hearing Alliance collaboration with GN.
  • Advised Novo Nordisk, a listed Danish multinational pharmaceutical company, on its acquisition of Ziylo, a University of Bristol spin-out company that has been pioneering the use of its platform technology - synthetic glucose binding molecules - for therapeutic and diagnostic applications.

Covington & Burling LLP's life sciences group attracts plaudits for its 'well-rounded' offering. Its expertise spans corporate transactions, regulatory issues, litigation and IP as well as areas such as data privacy, anti-corruption and  government affairs. It undertakes large-scale, cross-border licencing and other commercial agreements, sales and acquisitions and a range of contentious matters such as challenges to the Medicines and Healthcare Products Regulatory Agency. It is also advising on the digital healthcare sector. Grant Castle  is the highly experienced head of the London team and some of his senior partners include Paul Claydon (M&A, private equity and venture capital transactions); the 'excellent'  James Gubbins (corporate, technology transfers and IP) and Daniel Pavin (advisory and contentious IP and digital health technologies).

Practice head(s):Grant Castle

Other key lawyers:Paul Claydon; James Gubbins; Daniel Pavin

Testimonials

'They have an exceptionally deep understanding of the biotech and pharmaceutical industries.'

'They have strong subject-matter expertise in life sciences transactions.'

Key Clients

AstraZeneca

Horizon Discovery Group plc

Illumina Inc

Johnson & Johnson

Oxford BioMedica plc

Merck Sharpe & Dohme

Novartis International AG

ReNeuron Group plc

Roche

GlaxoSmithKline

Work highlights

  • Advised AstraZeneca in connection with the sale of the rights to Seroquel and Seroquel XR in the UK, China and other international markets to Luye Pharma Group Ltd.
  • Acting for Boehringer Ingelheim on a challenge to the Medicines and Healthcare Products Regulatory Agency's approval of a generic version of the  client’s drug Pradaxa in the UK Courts.
  • Advising Novartis on an appeal in the Court of Appeal regarding a judicial review involving the Secretary of State and 12 Clinical Commissioning Groups relating a recommendation to prescribe and dispense an unlicensed medicine in the treatment of blindness in the elderly over the client’s NICE approved drug Lucentis.
  • Successfully defended Roche in the first so-called financial penalties infringement case bought by the European Commission against a pharmaceutical company using powers under the Financial Penalties Regulation.
  • Assisted Sanofi in negotiating an amendment agreement to an existing collaboration and licence agreement, which expands the scope of the research collaboration between the parties with respect to mRNA-based cancer therapies.

Gowling WLG offers well-honed expertise in 'heavy' patent (and other types of IP) disputes together with commercial transactions including joint ventures, licensing and collaborations. Team head Patrick Duxbury and Luke Kempton  bring impressive scientific backgrounds to their transactional IP/regulatory practice; Ian Piggin handles corporate and structuring matters and associate Jenny Davies is a life sciences patent specialist who handles pharmaceutical, biotech and medical device advisory and contentious cases.

Practice head(s):Patrick Duxbury

Other key lawyers:Dr Luke Kempton; Ian Piggin; Jenny Davies

Key Clients

GlaxoSmithKline

Astrazeneca

Immunocore

ArgenX

Takeda

Heptares (Sosei Group Corporation)

Eisai Europe

Coloplast

VIB

ERS Genomics

Isogenica

Topas Therapeutics

Genomics PLC

Johnson & Johnson

KU Leven

Epidarex Capital

KWS BioTest Ltd

Bial Portela

Work highlights

  • Acting for GlaxoSmithKline on a patent infringement matter concerning technology for making very fine powders for use in certain inhaler products. The case resulted in only the second Arrow declaration ever awarded in the UK. The opponent has appealed the decision.
  • Acted for biotechnology company argenx in its global collaboration and license agreement with Halozyme Therapeutics Inc. Belgium-based argenx focuses on the clinical development of novel antibody-based therapies.
  • Advised Sosei Group Corporation on an agreement with Allergan to amend its 2016 global R&D and commercialisation partnership (worth approximately €3bn) between Allergan and Sosei’s subsidiary Heptares Therapeutics.
  • In a complex and long-running case, acting for Coloplast in a patent infringement case against MacGregor Healthcare in respect of the client's patent for urinary catheters.  Leave to appeal has been sought.
  • Acted for Takeda in a dispute with UCB over payments being made for a licence of patents from UCB to Takeda concerned with making humanised antibodies. The claim included payment of past royalties.

Clare Tunstall heads the life sciences and patent litigation practices at Pinsent Masons LLP, which is entrusted with a range of IP protection cases by pharma and biotech companies. Christopher Sharp also takes on patent litigation cases whilst Allistair Booth focuses on IP transactions such as asset sales and purchases, collaborations and licensing. The team also assists clients on financing (Charles Waddell) and UK and European regulatory regimes (Catherine Drew). The team has been enhanced by David Lancaster, whose expertise is in patent and SPC-related litigation, joining from Powell Gilbert LLP and the arrival of Nick Finnie from Novartis.

Practice head(s):Clare Tunstall 

Other key lawyers:Allistair Booth; Charles Waddell; Christopher Sharp; Catherine Drew; David Lancaster; Nick Finnie

Testimonials

'The team has an in-depth understanding of the industry and have a unique set of capabilities and skills dedicated to advise pharma clients across the whole spectrum. They are highly professional, always available and provide excellent, clear and practical advises. They can also rely on a global and European network of excellent lawyers.'

'They have one of most impressive track records of pharma patent litigation in the UK (if not the most impressive) and before the CJEU and have been involved in several landmark decisions in the past few years.'

'Clare Tunstall has a deep knowledge of the pharma industry, is an impressive tactician and one of the best patent litigators in the UK.'

'Charlotte Weekes is an excellent litigator and very good at explaining complex technical issues. Catherine Drew has a unique knowledge of regulatory law in the pharma industry. They each are very nice people to work with and always make sure the client is happy.'

Key Clients

Teva Pharmaceutical Industries

Accord Healthcare

JUUL Labs Inc

IP Group PLC

Oribiotech Limited

4D Pharma PLC

C4X Discovery PLC

Oncimmune PLC

Evgen PLC

Nodthera PLC

IBSA Institut Biochimique

F2G Limited

Work highlights

  • The team's work for Teva includes acting, as one of four claimants, in a challenge to the validity of two of Eli Lilly/ICOS Corporation's patents for tadalafil - one low dosing regime patent and one formulation patent.
  • Acting for Accord Healthcare against Celgene Corporation in relation to the revocation of three patent families covering the blockbuster cancer drug Revlimid.
  • Acting for C4X Discovery Limited on its licence and collaboration agreement with Indivior PLC for its lead Orexin agonist compound.
  • Acting for Abzena on the sale of the company to a fund managed by Welsh, Carson, Anderson & Stowe.
  • Acting for NodThera on the discovery and development of next generation NLRP3 inflammasome inhibitors for the treatment of diseases driven by chronic inflammation, on a Series A financing round for a total of £28m.

Powell Gilbert LLP is well known for its outstanding IP offering, especially patents, where it has been involved in many headline and highly complex cases, many of which have reached the Supreme Court. Dr Penny Gilbert is the well-known team head and 'shrewd tactician' Tim Powell is a seasoned IP litigator combined with broad advisory and regulatory experience. The team handles multi-jurisdictional litigation, advice on SPCs, licensing and collaborations. With  strong scientific backgrounds, Tim Whitfield, Dr Bethan Hopewell  and 'brilliantly clever' associate Joel Coles are recommended.

Practice head(s):Penny Gilbert

Other key lawyers:Tim Powell; Tim Whitfield; Bethan Hopewell; Dr Joel Coles

Testimonials

'They are a joy to work with, intensely intelligent and hard working. They are at the top table now for pharma patent cases - a force to be reckoned with.'

'Tim Powell is a shrewd tactician. He is calm and authoritative. He has my full trust, and I can't give much higher praise than that.'

'Bethan Hopewell is an excellent addition to the PG partnership. She gets it - the balance required to execute on a complex strategy.'

'Joel Coles is a rising star. Brilliantly clever and dogged in a fight.'

Key Clients

Actavis

Edwards Lifesciences

Garmin

GSK

Illumina

Biogen

Napp/Mundipharma

Kymab

UCB

Reckitt Benckiser

Royalty Pharma

Work highlights

  • Represented Actavis, a leading manufacturer of generic pharmaceuticals, in its long-running battle with Warner-Lambert concerning the blockbuster drug pregabalin (marketed by Warner-Lambert as Lyrica).
  • Successfully represented Biogen in proceedings before the UK High Court against AbbVie relating to biosimilars of AbbVie’s blockbuster drug Humira™ (adalimumab), currently the biggest selling prescription drug worldwide.  The court granted the first 'Arrow' declaration and established the availability of such protection in circumstances where a patentee has multiple pending patent applications.
  • Acting for Edwards Lifesciences in patent litigation - leading the UK case in the international patent battle over implantable heart valve repair devices.
  • Defending Kymab, a UK biotech company spun out of the Sanger Centre in Cambridge, in a patent infringement action brought by Regeneron (a US biotechnology company and currently one of the largest worldwide). The case is listed to be heard by the Supreme Court in 2020. The team was also successful in the Court of Appeal agreeng that Kymab should be allowed to continue a number of clinically important collaborations, including its ongoing work with the Bill and Melinda Gates Foundation.

Clyde & Co LLP offers the full range of practice areas to its life sciences clients; in addition to corporate/commercial, product liability, IP and  regulatory, it also provides public procurement, employment, property and tax teams. Ralph Cox has extensive experience in patent litigation and freedom to operate and acts for biotech and mid-sized and generic pharma companies. Corporate partner Simon Gamblin assists clients such as university spin-outs on complex licensing and commercialisation agreements including disputes arising from collaboration or licensing agreements. Claire Petts specialises in the areas of drug trials, product liability and claims/clinical negligence.

Practice head(s):Ralph Cox; Simon Gamblin

Other key lawyers:Claire Petts

Key Clients

CNA Hardy/ITH PharmaLtd

GlaxoSmithKline

The Doctors Laboratory Ltd/TDL Genetics Ltd

Oxford Biodynamics Plc

Oxsybio Ltd

Work highlights

  • Defending ITH Pharma in the product-liability claims brought against it alleging contamination of the baby food it manufactures.
  • Defending GlaxoSmithKline in a product-liability claim arising from historic exposure to Myodil (a viscousiodine-containing oil injected by lumbar puncture for screening for pathology of the spinal cord).
  • Advising Oxford Biodynamics Plc on an investment and cooperation agreement and drafting the documentation.
  • Advising Oxsybio on a fundraising and drafting and negotiating the necessary documentation for this £10m deal.
  • Defended TDL Genetics Ltd and The Doctors Laboratory in a series of patent infringement actions and appeals which included  revocation and counterclaims involving  patents relating to pre-natal testing for Down's syndrome.

Cooley (UK) LLP offers a range of specialisms to its life sciences clients, in particular on  transactional and IP matters. The highly experienced John Wilkinson assists clients in these areas and on regulatory and competition matters. Other core team members include Nicola Maguire, who advises on the IP aspects of transactions and Stephen Rosen.

DAC Beachcroft LLP has a well-established track record in dealing with significant pharmaceutical and medical product liability cases in the pharmaceutical and healthcare sectors. It excels in dealing with litigation and the regulatory issues connected with medical devices, clinical trials and consumer healthcare goods and pharmaceuticals. It frequently acts in connection with insurance claims and also handles related IP and commercial work. It has also formed a specialist MedTec offering. Alison Mcadams and Simon Pearl head the practice and Andrew Allan-Jones and Hamza Drabu are key advisors, the latter focuses on clinical research agreements and other commercial agreements.

Practice head(s):Alison McAdams; Simon Pearl

Other key lawyers:Andrew Allan-Jones; Hamza Drabu

Testimonials

'They have excellent and wide knowledge of the sector - extensive medical device expertise. Olya Melnitchouk is a rising star and  Simon Pearl and Alison McAdams are already top advisers.'

Key Clients

Novartis, Alcon and Sandoz N

BMI Healthcare N

Optegra N

AstraZeneca N

Draeger N

Ipsen Pharma

NHS Resolution and NHS Blood and Transplant Service

Clinimed

NHS England

Insurer clients specialising in insureds in the life sciences sector

including HDI, Newline, Zurich, Allianz, QBE, Catlin and CNA

Work highlights

  • Represented BMI Healthcare Group/Spire Healthcare Group on metal-on-metal hip replacement litigation which involved over 500 claimants alleging that the early failure of replacement hip products has resulted in pain and muscle damage.  
  • Advised Novartis; Alcon, its eye care subsidiary and Sandoz, its generics subsidiary regarding claims, regulatory advice on medicines and devices and on clinical trial matters.
  • Advised HDI on on a range of claims involving medicines and devices and also advised on regulatory matters, particularly regarding clinical trials.
  • Assisted Optegra UK Limited regarding the recall of intraocular lens and subsequent claims and regulatory issues.
  • Acting for NHS England in the Lyrica patent litigation between Warner-Lambert, Actavis and Mylan. The case involves a complete new look at second medical use patent claims and the role of doctors, pharmacists and NHS England in the prescription and dispensing of  pharmaceuticals. We created a new type of court order extending Norwich Pharmacal principles which led to NHS England issuing prescribing guidelines to every CCG and pharmacy in England.

Fieldfisher is home to an impressive range of expertise in the IP litigation and transactional fields together with regulatory regimes, competition, data privacy and related tax law. Team head Nicole Jadeja has expertise in commercial and regulatory matters together with a focus on IP and has represented clients in UK and ECJ courts as well as the EPO. Nicola Bex has considerable expertise in the medical device field in addition to drafting supply and licensing agreements, including those relating to clinical trials. Beatriz San Martin specialises in IP disputes in the sector and Sarah Ellson spearheads the regulatory team and advises on biosciences regulations.  Former co-head of the team Alison Dennis is joining Taylor Wessing LLP in early 2020.

Practice head(s):Nicole Jadeja

Other key lawyers:Beatriz San Martin; Sarah Ellson; Nicola Bex 

Key Clients

Abbott Laboratories

Sandoz

Align Technology Inc

GlaxoSmithKline

PerkinElmer Inc

Insulet

Roche Products Ltd (pharmaceuticals) and Roche Diagnostics Limited (medical devices)

Genomics England Limited

Stifel Nicolaus Europe (formerly Oriel Securities)

Smiths Medical

Work highlights

  • Acted for Roche Products in the judicial review of the NHS provision of its product bevacizumab (Avastin), the cancer drug. The Claimants were Bayer and Novartis and Roche was an interested party.  
  • Continuing to act for the Human Fertilisation and Embryology Authority on a  long-running judicial review dispute with the Assisted Reproduction and Gynaecology Centre in relation to the decision to change the information and statistical data about licensed clinics which HFEA publishes on its website in the discharge of its duties, under section 8 of the Human Fertilisation and Embryology Act 1990.
  • Advised Tristel plc, an AIM-listed life sciences company on its purchase of the Belgium-headquartered distribution business, Ecomed Group.
  • Acting for Sandoz, the generics arm of Novartis, in a dispute concerning the interpretation of the Supplementary Protection Certificate Regulation.  Sandoz is seeking revocation of GD Searle's SPC for darunavir, an antiretroviral used for the treatment of HIV on the basis that the SPC is invalid. The matter was appealed and a number of questions were referred to the European Court.
  • Acting for medical device company Align Technology on a range of matters, including drafting international agreements,  technology licensing and advising on compliance, regulatory, tax and competition law in addition to IP disputes.

Goodwin has a track record acting for life sciences companies and investors on corporate transactions such as M&A and IPOs as well as securities offerings and venture capital financings. It is especially expert in advising on early stage financings. Graham Defries, Andrew Harrow and Sophie McGrath are key advisors in these areas. The team has been greatly boosted with the hire of Malcolm Bates, David Mardle, Tim Worden and Adrian Rainey who joined in mid 2019 from Taylor Wessing LLP and bring a wealth of life sciences-focused corporate, commercial transactional and regulatory expertise.

Practice head(s):Graham Defries

Other key lawyers:Andrew Harrow; Sophie McGrath; Malcolm Bates; David Mardle; Tim Worden; Adrian Rainey

Key Clients

Advance Medical Solutions Group Plc

AM-Pharma Holding BV

Exscientia Limited

NodThera Limited

Gadeta BV

Galapagos NV

LumiraDx

Orchard Therapeutics

ReViral Limited

Staten Biotechnology BV

Work highlights

  • Advised Staten Biotechnology on its strategic collaboration with Novo Nordisk A/S to develop novel therapeutics for the treatment of triglyceride dyslipidaemia.
  • Advised Gadeta BV on its strategic collaboration with Kite, a Gilead company, to develop novel gamma delta T cell receptors therapies in various cancers.
  • Advised Orchard Therapeutics on its $225m IPO of American Depositary Shares.  JP Morgan, Goldman Sachs and Cowen served as the joint bookrunners on the deal. The proceeds will be put towards getting its three lead assets through regulatory filings for three gene therapies in the US and Europe.
  • Acted for Novartis BioVentures and Versant Venture Capital VI, L.P. as lead investors in the £29m  oversubscribed Series B equity funding round of Enterprise Therapeutics Limited.
  • Acted for F-Prime Capital and Eight Roads Ventures in an investment into Owkin Inc, a US corporation with a French operating subsidiary working on an artificial intelligence software product to improve the accuracy of medical diagnoses.

Kirkland & Ellis International LLP has entered the rankings as a result of 'stand-out achiever' Nicola Dagg and her team joining forces with the firm. The team includes Daniel Lim, who is highlighted for his 'excellent understanding of biotech and regulations', and litigator Katie Coltart, who has a background in biochemistry. With a 'keen intellect and considerable knowledge' Senior associate Jin Ooi  and Steven Baldwin are also core members of a team that has an established success rate in high-stakes patent litigation in the pharma and biosciences sectors. This is combined with the firm's financing and commercial capabilities.

Practice head(s):Nicola Dagg

Other key lawyers:Daniel Lim; Katie Coltart; Jin Ooi; Steven Baldwin

Testimonials

'Known for the highest-quality work to achieve the best results.  Top of their game and must be on everyone's list to consider using when a big matter needs an IP litigator.'

'They demonstrate a clear ability to excel in high-pressure situations.'

'Nicola Dagg is a stand-out achiever in the field. She  leaves no stone unturned and is hugely in demand.'

'The stand out individuals are Nicola Dagg, Jin Ooi and Katie Coltart. Nicola drives the technically strong and client-focused approach.'

'Jin Ooi is an associate to watch out for.  He has a keen attention to detail and will rapidly deploy his considerable knowledge of the facts and related case law to examine the situation at hand.  He has a natural curiosity and strong intellect which lends well to valuable insights and contributions. He is also calm and meticulously organised which ensures the smooth and quick development of a case, no matter how many moving and complex parts there are.'

'Daniel Lim has an excellent knowledge and understanding of biotech, as well as impressive knowledge of regulatory law.'

Key Clients

Regeneron

Pfizer

Novartis

Pfizer

Premaitha Health

Biomet

Work highlights

  • Acting for Regeneron Pharmaceuticals Inc in patent litigation against Kymab Ltd relating to Regeneron’s proprietary transgenic mouse platform for therapeutic antibody development, VelocImmune®. The matter has been listed for a Supreme Court hearing.
  • Acted for Pfizer in respect of infringement and validity proceedings in relation to  LYRICA® (pregabalin),  Pfizer’s blockbuster pain medicine which accounted for some billions of dollars in revenue. This complex case went to the Supreme Court and the team also assisted in the co-ordination of parallel litigation in a number of other jurisdictions.
  • Acting for Novartis (Afinitor)  in protecting everolimus (sold as AFINITOR®, VOTUBIA® and CERTICAN®) in the UK,  Europe and elsewhere. Conducted UK litigation, advising on patent strategies and secured an interim injunction to prevent the sale of generic everolimus.
  • Acted for the consortium consisting of EQT and Luxinva (a wholly owned subsidiary of the Abu Dhabi Investment Authority) on the CHF 10.2bn exclusive negotiations for the EQT-led consortium to acquire Nestlé Skin Health. This included  conducting the EU regulatory and IP due diligence for the deal.
  • The team is acting for a global pharma client in respect of a large-scale merger. The team is  handling the EU clearance and supervising clearances elsewhere.  

Linklaters LLP's healthcare practice is led by TMT/IP partner Marly Didizian and corporate partner Aisling Zarraga. It  offers a full service to its clients from corporate/M&A, commercial and funding to technology and IP in combination with a global network. It also handles investigations and data-protection issues in the pharmaceutical industry. Working with US and European colleagues, Yohan Liyanage focuses on IP and is handling a number of patent disputes. Georgina Kon assists clients from a technology perspective, including with data-protection issues.

Practice head(s):Marly Didizian; Aisling Zarraga

Other key lawyers:Georgina Kon; Yohan Liyanage

Work highlights

  • Continues to act for the Sanofi group and Regeneron Pharmaceuticals Inc. as co-defendants in a complex, high-value UK patent litigation action brought by Amgen. The dispute relates to a revolutionary new class of medical treatments that lower the level of cholesterol in the body.
  • Acting for Shire Pharmaceuticals in a complex UK patent litigation action brought  by CSL Behring. The dispute relates to the treatment of a rare, life-threatening blood disorder known as hereditary angioedema.
  • Acted as lead transaction counsel on Takeda Pharmaceutical Company's $62bn takeover offer for the innovative pharmaceutical company Shire plc.
  • Advising US-based Merck & Co in defending a long-running, high-profile trade mark infringement and breach of contract dispute against German-based Merck KGaA regarding use of the 'MERCK' name (the parties were originally part of the same company but are now separate).

Morgan, Lewis & Bockius UK LLP offers global expertise to life sciences clients, including in the biotech arena, especially on transactions, fund raisings and regulatory regimes. It can also bring in extensive competition/anti-trust expertise (Frances Murphy) while Timothy Corbet specialises in advising early stage biotechnology companies on capital raisings, listings and commercial matters. Thomas Cartwright assists on a range of corporate matters and 'trusted and extremely knowledgeable' consultant Paul Ranson  enhances the team with his wealth of regulatory and commercial know-how relating to the life sciences sector.

Practice head(s):Thomas Cartwright; Timothy Corbett

Other key lawyers:Frances Murphy; Paul Ranson

Testimonials

'A trusted, credible team with great wealth of knowledge and experience. The work is always well communicated and delivered in a timely manner. Paul Ranson is a trusted, experienced and extremely knowledgeable partner.  His work ethic, engagement and commitment in delivering agreed work are exceptional.'

Key Clients

Replimune Group Inc

Perrigo Company plc

Astellas Pharma Inc

Sanofi SA

SK Capital Partners

AstraZeneca plc

Shire Pharma (now Takeda)

uniQure NV

Merck

Clovis Oncology

GMP Orphan

Advanz Pharma (formerly Concordia)

Work highlights

  • The team worked with  uniQure NV, a Nasdaq-listed Dutch biotech company, in its registered $147m follow-on public offering of ordinary shares, which include the full exercise of the underwriter’s option to purchase additional shares.
  • Advised biotechnology company Replimune Group Inc in connection with its initial public offering of  common stock and listing on the Nasdaq Global Select Market.
  • Handled all antitrust aspects for Alphabet/Google and Google's sister subsidiary, Verily, in its proposed joint venture with ResMed, including approval from the European Commission after several months of scrutiny.
  • Advise AstraZeneca on a range of complex competition issues, including new and novel means of supplying and pricing medicines for use in hospitals and in GP surgeries and for dispensing by pharmacies, all following the restructuring of the NHS’s buying practices by the government and following the establishment of Monitor, the new regulatory authority.
  • Advising Bristol Myers Squibb in relation to a global policy review and implementation exercise.

Patent litigator Huw Evans, who is 'a pleasure to work with', heads the Norton Rose Fulbright practice and focuses on a broad range of IP-related transactions. Ian Giles handles anti-trust/competition matters for life sciences clients and Milana Chamberlain is a corporate finance lawyer who brings 'huge knowledge and passion' to her specialism in business ethics and anti-corruption. She advises clients on areas such as the UK Modern Slavery Act and  human rights in supply chains. The team's varied skills assist clients ranging from big pharma to biotech startups.

Practice head(s):Huw Evans

Other key lawyers:Ian Giles; Jonathan Ball; Milana Chamberlain;

Testimonials

'Huw Evans' expertise, practical approach and responsiveness made him a pleasure to work with.'

'Norton Rose Fulbright have a strong life science team with a good blend of functional expertise and they are all nice people to deal with - lawyers with a human touch.'

'Milana Chamberlin has provided excellent advice and guidance with huge knowledge and passion for her subject.'

Key Clients

BSN Medical

GlaxoSmithKline

Malin Corporation Plc

Oxford Nanopore Technologies

Pfizer

Reckitt Benckiser

Work highlights

  • Representing Oxford Nanopore Technologie in patent litigation brought against it by Pacific Biosciences of California. The client developed hugely disruptive technology in the DNA sequencing market, such that established player Pacific Biosciences (PB) is bringing various claims of patent infringement in the UK and the US.
  • Advising a healthcare client on an ongoing investigation by the Competition and Markets Authority into alleged excessive pricing contrary to the Chapter II prohibition.
  • Advised a global client on copyright registration and brand protection in China.
  • Advising a global client on the drafting of its distribution agreements with suppliers across the EU.  

RPC's 'razor sharp and thoughtful' team is headed by Dorothy Flower who specialises in product liability defence cases relating to medical devices and pharmaceutical products. She acts for a range of manufacturers and suppliers, often on the instructions of insurers, and also handles claims arising from clinical trials. The team is entrusted with some high-profile work including actions relating to breast implants and 'metal hips on metal' disputes; Peter Rudd-Clarke specialises in cases involving orthopaedic implant litigation. Rowan Brown  is also experienced in these areas and Genevieve Isherwood assists on medical malpractice and product liability claims.

Practice head(s):Dorothy Flower

Other key lawyers:Peter Rudd-Clarke

Testimonials

'The team demonstrates great understanding of our needs and a commitment to getting it right for us. It feels like more than just doing their jobs. They think strategically, give us alternative viewpoints, and have incredible attention to detail. I think of these individuals as colleagues.'

'Dorothy Flower is just brilliant, always there for us, and we have really enjoyed working with Genevieve Isherwood on recent issues - to the point where I will be sad when our current case is concluded!'

'These lawyers are razor sharp yet compassionate, thoughtful, and committed to getting the best outcome for us.'

Key Clients

Medisoft

BSI Group

Bard Pharmaceuticals

Heidelberg

Make Yourself Amazing

Corin Limited

Chubb

Royal Hospital for Neuro-Disability

NQBE European Operations

British Pregnancy Advisory Service

NAXA XL

Merete Medical GmbH

Work highlights

  • Represented Corin in the 'metal-on-metal' group litigation involving some 157 claims.
  • Representing the British Pregnancy Advisory Service  in an application for judicial review over abortion legislation.
  • Assisting BioPoly,  a US-based orthopaedic medical device manufacturer. Current work relates to a post-market registry study in the UK for a new type of knee prosthesis product. Also  provided regulatory and IP advice and assistance with the contractual agreements for the study.
  • Acted for Merck Sharp & Dohme Limited and its insurers Chubb with regard to a clinical trial brought by a trial subject who alleged complex, adverse consequences of participation.
  • Representing Bard Pharmaceuticals Limited in the defence of a claim being made against it for an alleged, accidental, opioid overdose.

Slaughter and May's client list ranges from some of the largest international life sciences companies through to start-ups, universities and research institutions, as well as investors, and it counts GlaxoSmithKline as a key client. It provides multi-jurisdictional cover and is especially adept in the realms of corporate/M&A and finance deals where it provides a 'flawless' service.  David Johnson spearheads corporate and commercial transactions together with Simon Nicholls. Susie Middlemiss takes on contentious and non-contentious IP matters.

Practice head(s): David Johnson;  David Johnson 

Other key lawyers:Simon Nicholls

Testimonials

'The team communicates very well internally so that there is never a lack of knowledge in case somebody else has to cover. The service is therefore flawless and consistent.'

Key Clients

Immunocore

GE Healthcare

Lonza

Bupa

Hikma Pharmaceuticals

Thermo Fisher Scientific

Oxford Nanopore

GlaxoSmithKline

Amyris

Work highlights

  • Advising GlaxoSmithKline plc on its agreement with Pfizer Inc. to combine their consumer health businesses into a new  joint venture with combined sales of approximately £9.8bn. GSK will have a majority controlling interest of 68% and Pfizer will have an equity interest of 32% in the joint venture.
  • Advised Shire plc on the takeover offer by Takeda Pharmaceutical Company Limited for the entire issued, and to be issued, ordinary share capital of Shire.
  • Advised GlaxoSmithKline plc on its acquisition of Novartis AG’s 36.5% stake in their Consumer Healthcare Joint Venture for a cash consideration of $13bn.
  • Advised Amyris Inc on its collaboration arrangements with a subsidiary of Yifan Pharmaceutical.
  • Advising Thermo Fisher Scientific on its proposed acquisition of the electron microscope peripherals business of Roper  Technologies Inc (the Gatan business). In addition to advising on the UK filing, it is coordinating with local counsel with respect to filings in the US and Austria, a matter valued at c.$925m.

Stephenson Harwood serves a range of pharma, biotech and healthcare clients, including startups, with a comprehensive range of expertise. This includes corporate and commercial; Andrew Edge has advised a number of major players in the sector on mergers, acquisitions and IPOs and Anthony Clare also advises on commercial and funding mandates.  Alexandra Pygall 'provides the highest quality advice' to her clients on all aspects of IP commercialisation including licensing and collaboration deals and routinely assists on the IP aspects of M&A. 'Excellent advisor' Rob Jacob also specialises in all aspects of IP advisory and contentious cases.

Practice head(s):Andrew Edge; Alexandra Pygall 

Other key lawyers:Anthony Clare; Rob Jacob

Testimonials

'High-quality advice, personable solicitors, great individual care and attention. A team who genuinely care and want to make a different to their clients whether to win, negotiate or settle.'

'Alexandra Pygall has an excellent technical background and provides the highest-quality advice.'

Key Clients

GSK

BTG plc

Shield Therapeutics Plc

Cell Medica Ltd

UCB

Astellas

Incyte

Piramal

TyraTech Inc

Acacia Pharma

Vernalis

Novacyt

Work highlights

  • Advised Shield Therapeutics in relation to the exclusive out-licensing arrangement negotiated with Norgine BV for the right to commercialise Feraccru (a treatment for iron deficiency)  in Europe, Australia and New Zealand.
  • Advised Piramal Enterprises Limited on the sale of Piramal Imaging SA to UK-based medical imaging services provider Alliance Medical Group, part of the Life Healthcare Group.
  • Advises Astellas Pharma Europe Limited on a wide range of commercial contracts including service agreements and distribution agreements across multiple jurisdictions, in relation to Astellas' marketed products, and logistics services agreements for delivery of products to pharmacies. Also advises on master agreements for the provision of marketing and regulatory affairs services and data protection.
  • Advising GlaxoSmithKline Plc on multi-jurisdictional trade mark, copyright, comparative advertising and unfair competition claims brought by GSK in relation to various duplications of the shape of an inhaler designed, manufactured and licensed by Celon Pharma SA,  a Polish pharmaceutical company.

    .

  • Advised AIM-listed life sciences company TyraTech in relation to the UK aspects of the merger with American Vanguard Corporation and the cancellation of admission of TyraTech's common stock to trading on AIM.

Taylor Wessing LLP's life sciences team includes Nigel Stoate, who heads up the patents practice and specialises in contentious work in a variety of industries in addition to life sciences. Simon Cohen also handles patent litigation together with pharma regulatory work and James Marshall is a patent litigator with a focus on the pharmaceuticals and telecommunications sectors. The firm can offer its life sciences clients an impressive range of expertise in areas including competition and capital markets. Malcolm Bates, David Mardle, Tim Worden and David Rainey have left the practice to join Goodwin. Alison Dennis has joined the team from Fieldfisher.

Other key lawyers:Alison Dennis; Nigel Stoate; Simon Cohen; James Marshall

Testimonials

'Extremely well informed and if someone doesn't have the knowledge, then my request is forwarded to the correct individual with the answer. Our company does business in a multitude of countries and Taylor Wessing is able to meet our legal and compliance needs for each country with ease.  It's a pleasure working with them.'

'Very pro-active as a team and as individuals. Easy to work with and excellent customer service. If an explanation is needed, one is given clearly and concisely.'

Key Clients

Cambridge Innovation Capital

Pfizer (Hospira)

TxCell S.A.

Oxford BioMedica plc

Generics (UK) Limited (trading as Mylan)

Teva

MiNA Therapeutics

Confo Therapeutics

Kymab Limited

Mylan

Work highlights

  • Represented Mylan in the long-running pregabalin litigation case.
  • Advised Teva Pharmaceuticals Europe BV on its divestments of portfolios of generic pharmaceutical products (approximately 260 medicinal products) in 24 EU jurisdictions to multiple purchasers.
  • Continues to assist and represent Pfizer in patent invalidity challenges in Europe. Following successful patent litigation in the UK Patents Court and the UK Court of Appeal, the team continues to assist and represent Pfizer in patent invalidity challenges in Europe.
  • Advising Accord Helathcare in relation to its long-running litigation with Gilead in respect of Gilead's SPC for its antiretroviral product Truvada which is used in the treatment of HIV and other viral infections.  
  • Advised longstanding client Oxford BioMedica plc on an exclusive worldwide licence of its gene therapy treatment for Parkinson's Disease.

Well known for its outstanding patent protection and enforcement capabilities, Carpmaels & Ransford LLP acts for an impressive range of big pharma and biotech clients. It also helps smaller and startup clients, many of which are involved in cutting-edge science, to grow. In addition to providing end-to-end patent abilities, it assists clients with areas such as licensing and collaborations. Specialist partners spearhead this work - David Wilson, Hugh Goodfellow,  Mark Chapman and James Warner - backed up by skilled teams. Patent litigator Simon Llewellyn  has joined the team from Bird & Bird LLP.

Practice head(s):David Wilson; Hugh Goodfellow; Mark Chapman; James Warner

Other key lawyers:Simon Llewellyn

Key Clients

Abraxis Bioscience (Owned by the Celgene biotechnology group)

Allergan

Celgene Corporation

Fibrogen

Foundation Hubrecht Organoid Technology

Gilead

Janssen Biotech, Inc. (a Johnson & Johnson company)

Johnson and Johnson

Novartis

Pacific Biosciences, Inc.

Stanford University / Forty Seven, Inc.

4D Pharma PLC

Work highlights

  • Acted for Abraxis BioScience LLC (owned by the Celgene biotechnology group) on a referral to the European Court of Justice regarding the law relating to SPCs. Abraxis’s SPC application was based on the ABRAXANE® authorisation and a related patent.
  • Acted for Novartis regarding a patent relating to its blockbuster medicine Exforge for the treatment of hypertension. Successfully defended the patent before the EPO against eight opponents and  also provided extensive support in national litigation in numerous countries.  
  • Represented Pacific Biosciences, a California-based company specialising in real time DNA sequencing in two High Court patent infringement and revocation proceedings between PacBio and Oxford Nanopore Technologies, a UK-based company specialising in nanopore sequencing methods.
  • Acted for Foundation Hubrecht Organoid Technology on worldwide patent and know-how licence agreement between Hubrecht Organoid Technology and JSR Corporation, the parent company of Crown Bioscience.  
  • Acted for Janssen Biotech (a Johnson & Johnson company) in a patent revocation action relating to a patent  for the treatment of psoriasis which was commenced by Lilly.

Dechert LLP is well regarded for its transactional and finance work in the life sciences sectors. It advises on acquisitions, sales, IPOs as well as commercial work such as licensing and collaborations. Corporate partner, Douglas Getter is team head and the 'brilliant and incisive' Robert Darwin handles corporate and private equity matters for clients in the life sciences sector - he  joined the team from Hogan Lovells International LLP in late 2018. US qualified Patrick Lyons is a capital markets lawyer with a strong focus on the life sciences sector.

Practice head(s):Douglas Getter; Robert Darwin; Patrick Lyon

Testimonials

'They are very service minded, accessible, with deep industry knowledge.'

'They are a great support to their clients. Fantastic service attitude, engagement and industry knowledge. They are also fun to work with.'

'Robert Darwin is very well connected for a partner his age. Highly engaged, and outstanding technical skills.'

'Robert Darwin is an up-and-coming corporate/PE professional, with astonishing experience and industry knowledge. He is a very adept negotiator who knows when to be tough and when to be pragmatic.'

Key Clients

Merck KGaA

Medincell

PeproTech Inc

Judges Scientific plc

Work highlights

  • Advising new client Merck KGaA on its its strategic immuno-oncology collaboration with F-star, a clinical-stage biopharmaceutical company, including in relation to an acquisition option valued at up to $1bn.
  • Advised MedinCell on its IPO on the regulated market of Euronext.  MedinCell is a technology-based pharmaceutical company and the deal is valued at  €35m.
  • Advising a new life sciences research company on the strategic options relating to the potential  sale of the company.
  • Advising a new R&D client in connection with a clinical trial agreement and a capital raising.

Latham & Watkins serves life sciences companies ranging from big pharma to small bio-techs and also counts funds investing in the sector among its clients. It also offers the advantage of a global network. It is largely focused on transactional work and corporate partner Robbie McLaren handles areas such as cross-border acquisitions, and capital raisings. Fellow co-head Gail E Crawford handles cases on the tech side and includes all aspects of data privacy as a specialism. Edward Barnett deals with M&A transactions, commercial and governance matters and includes GlaxoSmithKline as a client. Frances Stocks Allen and Emily Cridland are noted associates in the team.

Practice head(s):Gail Crawford; Robbie McLaren

Other key lawyers:Edward Barnett; Frances Stocks Allen; Emily Cridland

Testimonials

'There is a uniformity in quality of service regardless of which lawyer is assigned to the task. They have a breadth of expertise across geographies and specific areas of M&A law.'

'Edward Barnett makes himself available to provide the strong voice of authority during crucial periods of the negotiation.'

'Frances Stocks Allen and Emily Cridland are both relatively young but come across as very seasoned in front of counterparties. Very responsive, hardworking, and just all-round pleasant people to work with.'

 

Key Clients

Abcam

Allergan

Amgen

Astellas Pharma

GlaxoSmithKline

Norgine

Novartis

Novo Holdings

Pharmathen

SiemensHealthineers

SOBI

Theramex

Zogenix

Work highlights

  • Representation of JP Morgan as financial advisor and lead financial arranger to Takeda Pharmaceuticals in connection with the acquisition by Takeda Pharmaceutical Company of Shire, the Ireland-based biopharmaceutical company.
  • Representation of GHX Europe GmbH, a subsidiary of Global Healthcare Exchange, in connection with its acquisition of the core business of Medical Columbus, a Germany-based developer of healthcare procurement software.
  • Representation of Theramex, a global specialty pharmaceutical company dedicated to women’s healthcare, in connection with the acquisition of the international women’s healthcare assets of Teva Pharmaceutical Industries Ltd. A deal valued at  $703m.
  • Advising Siemens AG on the IPO of its Healthineers unit on the Regulated Market (Prime Standard) of the Frankfurt Stock Exchange, a matter valued at €4.2bn.
  • Advised MeiraGTx Holdings plc, the holding company for a clinical stage gene therapy company, in connection with its IPO on the NASDAQ.

James Fry heads the Mills & Reeve LLP multi-practice life sciences offering which is valued for its 'in-depth biotech sector knowledge'. Fry brings wide experience of transaction in the technology/digital health and IP fields including research collaborations and clinical trial agreements. Mark Pearce handles contentious and non-contentious IP matters and the team also provides expertise in areas including employment (Melanie James) and corporate finance (Zickie Lim). Other IP experts in the team include Alasdair Poore.

Practice head(s):James Fry

Other key lawyers:Mark Pearce; Alasdair Poore; Melanie James; Zickie Lim

Testimonials

'Mills & Reeve have a strong focus on the biotech sector and are also well placed to meet the needs of small- and medium-sized companies, who typically have small- and medium-sized legal budgets. They also provide a high level of partner contact time. These attributes differentiate them from their peers.'

'They have very good engagement with the biotech/pharma community, facilitating networking within the industry. All partners and associates we work with are briefed on precedents and ways the firm has in the past preferred to handle matters, whilst always mindful that current circumstances/business climate may warrant a different approach. Exceptional availability and responsiveness.'

'I have valued the work that James Fry has done for us. He takes a practical/ commercial approach and I have been impressed with his ability to grasp some quite complicated aspects of our work.'

The Mishcon de Reya LLP team helps a broad range of life sciences clients on both contentious and non-contentious cases in the IP and regulatory spheres, in addition to areas including contractual and competition law disputes.  It also has a noteworthy track record in obtaining search and seizure orders against counterfeiters in the pharmaceutical sector. Martyn Hann leads this work and David Rose has expertise in all areas of IP protection including data base rights. Managing associate Stefania Littleboy specialises in non-contentious matters including joint ventures, licensing and co-existence agreements.

Practice head(s):Martyn Hann

Other key lawyers:David Rose; Stefania Littleboy

Key Clients

Sanofi

GlaxoSmithKline plc

Shire plc

Shionogi Limited

Dr Reddy's Laboratories (UK) Limited

Perrigo Group (including Rafton Laboratories, Elan Pharmaceuticals, Rosemont Pharmaceuticals and Omega Pharma)

OBG Pharmaceuticals (including Pharmaserve Northwest Limited)

Lupin Limited and Lupin (Europe) Limited

Hempire Limited

Work highlights

  • Acted for the claimant, Lupin, in successful proceedings invalidating Gilead's SPC relating to Gilead's Truvada product.
  • Representing Dr Reddy’s Laboratories in defending a claim for patent  infringement brought by Warner-Lambert/Pfizer in relation to pregabalin and Dr Reddy’s counterclaim for revocation.
  • Advised a leading pharmaceutical company on an extremely serious data theft issue.
  • Acted for a number of companies with regard to the law and regulation relating to the cultivation of cannabis and the subsequent use of extracts for the use in healthcare products.
  • Advising a number of global and UK life sciences companies on GDPR and data protection matters, including in respect of particularly in respect of clinical data sharing and clinical data automisation  

Janita Good leads Osborne Clarke LLP's offering to its life sciences clients which is focused on transactional work, strategic investments, joint ventures and cross-border M&A deals. Recent work has included IPOs, business restructurings and debt and equity restructuring. Matthew Edwards joined the team in January 2019 and Mathew Oliver has joined from Bird & Bird LLP.

Practice head(s):Janita Good

Other key lawyers:Matthew Edwards; Mathew Oliver

Key Clients

Sensyne Health plc

Takeda Ventures

Takeda Pharmaceuticals Company

Grifols SA and Grifols UK Limited

Biotecnol

Millennium Pharmaceuticals Inc

GAMA Healthcare

UniPhar Group plc

Green Biologics Limited

Stryker European Operations BV

Universal Health Services Inc

Work highlights

  • Advised Sensyne Health plc in connection with its group reorganisation and  successful £225m AIM market IPO, the first healthcare AI flotation.
  • Advised Takeda on its $105m option to acquire Akaza Bioscience Limited; the transaction includes an initial equity investment and complex licence agreements.
  • Advised Millennium Pharmaceuticals Inc on amendments of its $100m option to acquire  GammaDeltaTherapeutics - the revised deal structure was proposed in 2018 to incentivise certain key employees.
  • Advised Biotecnol on the sale of its immuno-oncology pipeline and respective technologies to Chiome Bioscience Inc.
  • The team is the sole advisor to Grifols SA and Grifols UK Limited, the global healthcare company (bioscience, diagnostic and hospital).

The Squire Patton Boggs team, led by Andrew Wilkinson, handles commercial and regulatory work as core specialisms and is known for its advertising, promotional clearance and product labelling know-how. Consultant Adrian Spooner, who is also a qualified pharmacist, acts for life sciences clients in respect of regulatory, IP and commercial matters and Paul Jinks' expertise includes commercial work relating to R&D, supply arrangements and product recall cases.

Practice head(s):Andrew Wilkinson

Other key lawyers:Adrian Spooner; Paul Jinks

Charlotte Tillett heads the Guildford-based Stevens & Bolton LLP team whose core work for life sciences clients encompasses IP, regulatory, commercial and competition matters. Tillett, who has a science background, leads on much of the IP commercialisation work including licensing, joint development agreements and IP restructuring.  Michael Frisby handles the litigation, arbitration and ADR work and Beverley Flynn undertakes commercial work on an array of contracts as well as data protection issues. Gustaf Duhs has expertise in competition, EU Law and regulatory issues in the life sciences sector.

Practice head(s):Charlotte Tillett

Other key lawyers:Michael Frisby; Beverley Flynn; Gustaf Duhs

Key Clients

Institute of Cancer Research

Aguettant Limited

SecurMed UK

Glenmark Pharmaceuticals

Lambda Therapeutic Ltd

Accord Healthcare Limited

inVentiv Health

Chas A Blatchford & Sons Ltd

NextPharma Technologies

Sanofi Synthelabo Ltd

Scitech Engineering Ltd

Lonza Biologics Plc

Royal Philips

Philips Healthcare

Zeta Biopharma GmbH

Rayner Intraocular Lenses Limited

iCareHealth (UK) Ltd

MedAnnex Ltd

Work highlights

  • Advising SecurMed, the lead entity on the UK’s implementation of the Falsified Medicines Directive and associated Delegated Regulation.
  • Advising Lonza Biologics plc in relation to its patent and know-how licensing which included the negotiation of in and out licences relating to gene expression technology patents.
  • Continuing to advise The Institute of Cancer Research on two large, specialist R&D projects.
  • Advised Royal Philips, a global leader in health technology, on its acquisition of the entire issued share capital of medical device specialist Remote Diagnostic Technologies Limited. This included advising on merger control risks and associated regulatory issues.
  • Advising Chas A Blatchford & Sons 'in the matter of Otto Bock HealthCare North America Inc Federal Trade Commission’ inquiry and case.

Interview with...

Law firm partners and practice heads explain how their firms are adapting to clients' changing needs

Interview with...

Law firm partners and practice heads explain how their firms are adapting to clients' changing needs

International comparative guides

Giving the in-house community greater insight to the law and regulations in different jurisdictions.

Select Practice Area

GC Diversity and Inclusion Report

In partnership with...

Press releases

The latest news direct from law firms. If you would like to submit press releases for your firm, send an email request to

Legal Developments in London for Pharmaceuticals and biotechnology

Legal Developments in the UK

Legal Developments and updates from the leading lawyers in each jurisdiction. To contribute, send an email request to
  • Court of Justice rules on source of income for Derivative Residence applications

    On 2 October 2019, the Court of Justice delivered its judgment in Bajratari v Secretary of State for the Home Department (Directive 2004/38/EC) Case C-93/18 which concerns Chen applications and the source of funds for self-sufficiency. 
  • End of the ‚Äėcentre of life test‚Äô in Surinder Singh cases?

    In the recent case of¬† ZA (Reg 9. EEA Regs; abuse of rights) Afghanistan ¬† [2019] UKUT 281 (IAC ), the Upper Tribunal found that there is no basis in EU law for the centre of life test, as set out in Regulation 9(3)(a) of the Immigration (European Economic Area) Regulations 2016 (the ‚ÄúRegulations‚ÄĚ). It further found that it is not to be applied when Judges assess ¬†Surinder Singh ¬†cases that appear before them.
  • Terms of employment as a sole representative

    In this article we examine the working arrangements of sole representatives, looking at the terms and conditions of employment that the Home Office will expect a sole representative to have in order to qualify as a representative of an overseas business.  
  • Can Sole Representatives Be Shareholders?

    The Immigration Rules require that an applicant for a¬† sole representative visa ¬†is not ‚Äúa¬† majority shareholder in the overseas business‚ÄĚ.
  • Immigration Skills Charge - A Guide for Employers

    As a Sponsor, you may be required to pay the Immigration Skills Charge (ISC) each time you sponsor a migrant in the  Tier 2 General  or  Intra-Company Transfer (ICT) Long-term Staff  subcategory.
  • 5 FAQS about paragraph 320(11)

    In applications for entry clearance where the applicant has a negative immigration history in the UK, the application may be refused under the general grounds for refusal, which are found in part 9 of the Immigration Rules. Where an applicant has ¬†‚Äėpreviously contrived in a significant way to frustrate the intentions of the Immigration Rules‚Äô,¬† the application could be refused under paragraph 320(11). In this post we look at five frequently asked questions about paragraph 320(11).¬†
  • Multiple nationality and multiple citizenship (including dual nationality and dual citizenship)

    British nationality law permits multiple nationality and multiple citizenship, including dual nationality and dual citizenship.
  • Applying for Indefinite Leave to Remain in the Exceptional Talent or Promise Category

    The  Exceptional Talent  and Exceptional Promise categories are for individuals who are recognised leaders or emerging leaders in their field of expertise. There are a number of endorsing bodies for lots of different fields of work, including  artists and musicians ,  architects ,  digital experts ,  scientists  and  academics . While there isn’t an endorsing body for every expert, the growing list means that many individuals could enjoy the flexibility that this category has to offer. 
  • PARALLEL PROCEEDINGS ‚Äď CIVIL AND CRIMINAL

    Syedur Rahmanconsiders the factors that determine when civil proceedings can go ahead before,or at the same time as, criminal proceedings relating to the same circumstances.
  • Rights of appeal after the Immigration Act 2014

    The Immigration Act 2014 (‚Äúthe 2014 Act‚ÄĚ) reduced the circumstances in which the refusal of an immigration application will give rise to a right of appeal.¬†The¬† explanatory notes ¬†to the 2014 Act state that the Act was intended to restructure rights of appeal to the Immigration Tribunal. Previously, a right of appeal to the Immigration Tribunal existed against any of the 14 different immigration decisions listed in s.82 of the¬† Nationality, Immigration and Asylum Act 2002 ¬†(‚Äúthe 2002 Act‚ÄĚ). As explained below, whether or not the refusal of an immigration application currently generates a right of appeal depends on the subject matter of the application rather than its categorisation.

Press Releases in the UK

The latest news direct from law firms. If you would like to submit press releases for your firm, send an email request to